Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Atea Pharmaceuticals
Biotech
Atea's COVID antiviral fails to halt hospitalizations in phase 3
Atea Pharmaceuticals’ antiviral has failed another COVID-19 trial, but the biotech still holds out hope the candidate has a future in hepatitis C.
James Waldron
Sep 13, 2024 10:10am
Atea rejects 'undervalued' offer from Concentra
May 30, 2023 7:51am
Concentra rebounds with a shot at COVID-19-focused Atea
May 22, 2023 11:20am
Atea dumps dengue drug as forecast R&D timelines, costs spiral
Mar 1, 2023 6:50am
Atea sticks it out with COVID antiviral and taps Merck HCV drug
Jan 7, 2022 9:50am
Atea will try to pair failed COVID-19 drug with other compounds
Dec 15, 2021 11:20am
